Metamizol Mabo (Metamizole Magnesium)

Metamizole magnesium works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins—key mediators of pain, fever, and inflammation. Lower prostaglandin levels diminish peripheral nociceptor activation and central fever signaling, resulting in analgesic and antipyretic effects.

The dosage of Metamizol Mabo is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Healthcare professionals set the appropriate strength, frequency, and duration according to clinical guidelines and individual needs.

Safety data for metamizole magnesium during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Metamizol Mabo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizole magnesium offers strong analgesic and antipyretic activity, often considered when standard NSAIDs or paracetamol are inadequate. Unlike many NSAIDs, it has minimal anti‑inflammatory effect, but it carries a risk of rare blood disorders, which requires careful monitoring compared with other pain relievers.

Metamizol Mabo should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme heat or humidity to maintain its stability.

Metamizol Mabo is administered orally. The tablet or capsule should be swallowed whole with a glass of water and taken according to the prescriber’s instructions. It is not intended for crushing, chewing, or sublingual use.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis. Hepatic dysfunction and renal impairment are also rare but significant adverse events that require immediate medical attention.

Metamizol Mabo should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, in patients with severe liver or kidney disease, and in those who have experienced prior agranulocytosis. It is also contraindicated in patients for whom alternative safer analgesics are appropriate.